Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.80|
|52 Week High||US$0.21|
|52 Week Low||US$2.67|
|1 Month Change||0.10%|
|3 Month Change||-25.14%|
|1 Year Change||151.97%|
|3 Year Change||-94.11%|
|5 Year Change||-99.96%|
|Change since IPO||-99.99%|
Recent News & Updates
Is Avinger (NASDAQ:AVGR) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Avinger shares fall after Q1 results fail to impress Wall Street
Avinger shares slide ([[AVGR]] -8.9%) after the company posted first-quarter revenue that narrowly beat Wall Street estimates, but failed to impress investors. Total revenue was $2.6M for the first quarter of 2021, an increase of 13% from the prior-year period, beating analysts' estimate by $0.12M.The company's topline growth during the quarter
|AVGR||US Medical Equipment||US Market|
Return vs Industry: AVGR exceeded the US Medical Equipment industry which returned 34.6% over the past year.
Return vs Market: AVGR exceeded the US Market which returned 33% over the past year.
Stable Share Price: AVGR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AVGR's weekly volatility has decreased from 20% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
Is Avinger undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVGR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVGR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: AVGR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVGR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVGR is good value based on its PB Ratio (4.4x) compared to the US Medical Equipment industry average (4.6x).
How is Avinger forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVGR's revenue (31.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: AVGR's revenue (31.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVGR's Return on Equity is forecast to be high in 3 years time
How has Avinger performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVGR is currently unprofitable.
Growing Profit Margin: AVGR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVGR is unprofitable, but has reduced losses over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare AVGR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVGR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).
Return on Equity
High ROE: AVGR has a negative Return on Equity (-96.4%), as it is currently unprofitable.
How is Avinger's financial position?
Financial Position Analysis
Short Term Liabilities: AVGR's short term assets ($33.7M) exceed its short term liabilities ($6.5M).
Long Term Liabilities: AVGR's short term assets ($33.7M) exceed its long term liabilities ($14.4M).
Debt to Equity History and Analysis
Debt Level: AVGR's debt to equity ratio (66.2%) is considered high.
Reducing Debt: AVGR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVGR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVGR has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 22.5% each year.
What is Avinger current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVGR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVGR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Soinski (59 yo)
Mr. Jeffrey M. Soinski, also known as Jeff, has been Chief Executive Officer, President and Director of Avinger, Inc. since December 29, 2014. From Avinger’s formation in September 2009 until the acquisiti...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD504.90K) is about average for companies of similar size in the US market ($USD545.11K).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
Experienced Management: AVGR's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: AVGR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.1%.
Avinger, Inc.'s employee growth, exchange listings and data sources
- Name: Avinger, Inc.
- Ticker: AVGR
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$76.378m
- Shares outstanding: 95.35m
- Website: https://www.avinger.com
Number of Employees
- Avinger, Inc.
- 400 Chesapeake Drive
- Redwood City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:20|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.